SCHEMBL9907392

SCHEMBL9907392

[C-]#[N+]c1cc(Cl)ccc1-c1nccc2ccc(C(=O)OC)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
MAP2K4 P45985 1/20 0.39
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
ALPL P05186 1/20 0.36
PLAU P00749 1/20 0.36
KDM4E B2RXH2 1/20 0.36
KDM6B O15054 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN9A Q15858 4/20 0.35
CSNK2A1 P68400 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907395 0.87 PLAU (0.43) CSNK2A2CSNK2BMAP2K4MAPTPLAU
SCHEMBL9907378 0.86 ALOX15 (0.41) ALOX15HTTNR1H4MAPTKDM4E
SCHEMBL9907377 0.85 ALPL (0.47) CSNK2A2CSNK2BMAP2K4ALOX15HTT
SCHEMBL9907366 0.84 KMO (0.44) CSNK2A2CSNK2BMAP2K4ALOX15HTT
SCHEMBL9907916 0.81 HTR2B (0.44) PLAU
SCHEMBL9909212 0.81 NR1H4 (0.40) CSNK2A2CSNK2BMAP2K4ALOX15HTT
SCHEMBL9907429 0.79 ALOX15 (0.37) MAP2K4ALOX15HTTNR1H4KDM4E
SCHEMBL9907376 0.76 TP53 (0.44) ALOX15HTTMAPTKDM4EKDM6B
SCHEMBL9907365 0.74 TP53 (0.47) ALOX15HTTNR1H4POLBKDM4E
SCHEMBL9907334 0.72 CYP19A1 (0.49) ALOX15HTTPOLBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CSNK2A2 4132/4885CSNK2B 4303/4885MAP2K4 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.